Safety of anti-tumor necrosis factor therapy in inflammatory bowel disease
Frank Hoentjen(Radboud University Nijmegen), Ad A. van Bodegraven(Vrije Universiteit Amsterdam)
Cited by 115
Related Papers
Circulating Vα24+ Vβ11+ NKT Cell Numbers Are Decreased in a Wide Variety of Diseases That Are Characterized by Autoreactive Tissue Damage
|Clinical Immunology|2001|270
IBD risk loci are enriched in multigenic regulatory modules encompassing putative causative genes
|Nature Communications|2018|252
Prognostic Factors for Advanced Colorectal Neoplasia in Inflammatory Bowel Disease: Systematic Review and Meta-analysis
|Gastroenterology|2020|233
Reduction of Colitis by Prebiotics in HLA-B27 Transgenic Rats Is Associated with Microflora Changes and Immunomodulation
|Inflammatory Bowel Diseases|2005|215
Ustekinumab for Crohn’s Disease: Results of the ICC Registry, a Nationwide Prospective Observational Cohort Study
|Journal of Crohn s and Colitis|2019|183